A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease
Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, Waichunas D, Bumgarner L, Bourdette D, Silbert L, Kaye J
Journal of Alzheimer's disease : JAD · 212 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute on Aging
- Gobierno
- National Center for Research Resources
- Gobierno
- NCRR NIH HHS
- Gobierno
- NIA NIH HHS
- Subvenciones
- National Institute on Aging (AG 08017); National Center for Research Resources (M01RR00334); National Institute on Aging (P30-AG008017); National Center for Research Resources (M01RR000334); National Center for Research Resources (UL 1RR024140); National Institute on Aging (R21AG023805); National Institutes of Health (AG‐08017)
Según 5 financiadores declarados.
Publicación
- Publicado
- 2013-10-29 · J Alzheimers Dis · vol. 38 · número 1 · págs. 111–120
- Editorial
- IOS Press
- Citado
- 288 citas · más que el 100% de estudios similares · 16.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 39 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC
- Áreas de investigación
- Fatty Acid Research and Health · Alzheimer's disease research and treatments · Dementia and Cognitive Impairment Research
- Palabras clave
- Alzheimer's disease, omega-3 fatty acids
- MeSH
- humans, alzheimer disease, thioctic acid, fatty acids, omega-3, f2-isoprostanes, activities of daily living, analysis of variance, pilot projects, double-blind method, cognition disorders, mental status schedule, aged, aged, 80 and over, middle aged, female, male, outcome assessment, health care
11 autores
- Lynne H. Shinto🇺🇸 · autor de correspondenciaOregon Health & Science University
- Joseph F. Quinn🇺🇸Oregon Health & Science University; Portland VA Medical Center
- Thomas Jude Montine🇺🇸University of Washington
- Hiroko Hayama Dodge🇺🇸Oregon Health & Science University
- William R. Woodward🇺🇸Oregon Health & Science University
- Sara Baldauf-Wagner🇺🇸Oregon Health & Science University
- Dana Waichunas🇺🇸Oregon Health & Science University
- Lauren Bumgarner🇺🇸Oregon Health & Science University
- DENNIS N. BOURDETTE🇺🇸Oregon Health & Science University; Portland VA Medical Center
- Lisa C. Silbert🇺🇸Oregon Health & Science University; Portland VA Medical Center
- Jeffrey Alan Kaye🇺🇸Oregon Health & Science University; Portland VA Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer's disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid (ω-3 + LA) compared to placebo on oxidative stress biomarkers in AD. The primary outcome measure was peripheral F2-isoprostane levels (oxidative stress measure). Secondary outcome measures included performance on: Mini-Mental State Examination (MMSE), Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL), and Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog). Thirty-nine AD subjects were randomized to one of three groups: 1) placebo, 2) ω-3, or 3) ω-3 + LA for a treatment duration of 12 months. Eighty seven percent (34/39) of the subjects completed the 12-month intervention. There was no difference between groups at 12 months in peripheral F2-isoprostane levels (p = 0.83). The ω-3 + LA and ω-3 were not significantly different than the placebo group in ADAS-cog (p = 0.98, p = 0.86) and in ADL (p = 0.15, p = 0.82). Compared to placebo, the ω-3 + LA showed less decline in MMSE (p < 0.01) and IADL (p = 0.01) and the ω-3 group showed less decline in IADL (p < 0.01). The combination of ω-3 + LA slowed cognitive and functional decline in AD over 12 months. Because the results were generated from a small sample size, further evaluation of the combination of omega-3 fatty acids plus alpha-lipoic acid as a potential treatment in AD is warranted.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.